e4p cema16 sa brochure v26

Overcome barriers to entry embrace an access-based marketing strategy

Sandton Johannesburg | March 8ndash9 | The only forum connecting pharma government and payers

COMMERCIAL EXCELLENCE AND MARKET ACCESSSOUTH AFRICA 2016

wwweyeforpharmacomsouthafrica

CollaborateEstablish relationships with all your key stakeholders industry

leaders and innovators

NetworkSpend over 6 hours networking

with 100+ pharma experts payers and key decision makers

Learn25+ thought leaders help you maximize

your learning in just 2 days with industry-led agenda case studies and panel discussions

efpCEMA

Dr Konji SebatiCEOIPASA

Jaime Ceacutesar de Moura OliveiraImmediate Past DirectorANVISA (Brazilian FDA)

Inez NaiduHead of Medicines UnitDiscovery Health

Gerrit DoevendansHead of Market Access South AfricaBoehringer Ingelheim

Gerdi StrydomHead of Health amp Value Southern AfricaPfizer

Belinda BhoodooDirector Corporate Affairs amp Market AccessEli Lilly amp Co

FOSTER COLLABORATIVE THINKING and consensus amongst various stakeholders

REMOVE BARRIERS TO PRESCRIBING Encourage cross-functional working across your 3Ms bull Marketing bull Market Access bull Medical teams

DESIGN WITH YOUR PAYERS Donrsquot just design your strategy for payers design it with them ndash and build long-term partnerships

MAP YOUR MARKET WITH INTELLIGENCE AND PRECISION And better prepare for future submissions

Gold Sponsor Strategic Partners Media Partners

LimitedPasses

Available

CEMA South Africa 2016 is the arena for senior level pharma executives across the 3Ms (Market Access Marketing and Medical) Theyrsquoll be joining government private medical aids payers and key decision makers who are keen to escape silos and learn how to best work together to build a more robust and widely accessible healthcare system for South Africa

The summit will help the commercial marketing and medical teams to work together to ensure the message shared to all stakeholders is consistent Furthermore yoursquoll have the opportunity to get clear guidelines from government and payers in terms of what they need from you in order to guarantee market entry and patient access to essential medicines

Over 2 days this event will inspire constructive debate and foster collaboration it has been specially designed for South African pharma and is the only one to finally give pharma a voice Not only will you learn from keynote panels exclusive case studies and real life business models from 25+ expert speakers yoursquoll also have the opportunity to speak directly with the key decision makers This is an event only for those who are serious about tackling the obstacles preventing South African health development

With all of this at your fingertips yoursquoll leave with genuine insights on how to achieve true commercial success and remove barriers to prescribing

Reserve your place amongst the most innovative minds in commercial marketing and market access ndash visit our website to register wwweyeforpharmacomsouthafrica or use the registration form enclosed

See you in Johannesburg

Welcome to the eyeforpharma Commercial Excellence and Market Access (CEMA) 2016 Summit Herersquos what attendees have

said about our previous commercial and market access events

Donrsquot just take our word for it

ldquo I found the congress exceptionally informative especially at this time when the pharma industry is going through a major change in defining new commercial modelrdquo

Quentin van der Merwe Sales Excellence Director GlaxoSmithKline

ldquo I came away from the conference feeling like I had some useful insights to share with my colleagues and ideas that could be implemented easily to further enhance our strategyrdquo

Carlyn Villani Brand Manager Roche

ldquo A fascinating meeting of diverse speakers who outlined numerous themes around the need to prove the validity and trustworthiness of RWE versus RCTs with an emphasis on ldquoreal timerdquo versus ldquoreal worldrdquo Thank you eyeforpharmardquo

Karel Mechelse Market Access Strategy Leader Bayer

ldquo Marketing with a purpose is all about creating unique and sustained value for patients and familiesenabling them with differentiated solutions to live the life they choose rather than one dictated by the diseaserdquo

Bharat Tewarie EVP amp Chief Marketing Officer UCB

Achieve real pharma- payer collaboration to streamline market access

bull Speak directly with Discovery Health and Metropolitan to better understand the decision making process and develop a better strategy for your future submissions

bull Learn what physicians find valuable and start supporting them to build long-term relationships and secure optimal market share

Optimize pricing and provision to guarantee entry to market

bull Make the shift from maximum to optimum pricing to create a sustainable business model

bull Evaluate strategies to address supply security and discuss how pharma can collaborate with government to ensure access to essential medicines

bull Work with the Pricing Committee to develop a winning methodology in preparing HTA dossiers

Master cross-functional collaboration to increase patient access to essential drugs and boost returns

bull Integrate a market access approach into your marketing strategy to ensure a consistent message with all customers and stakeholders

bull Improve the reputation of sales teams despite reduced resources

Agenda at a glance


Shakira BrowneHead of Commercial Excellence South Africa

Giselle QuartinHead of Marketing South Africa

Blair GottschoHead of Operations

Speaker faculty includes



Martin van den BergHead of MarketingBoehringer Ingelheim

Avinash DhanirajHead of CommercialMylan


Jacques SnymanHead of South AfricaISPOR


Ali HamdulayGeneral Manager Provider NetworksMetropolitan

Tania LennonHead Of Executive Leadership Talent amp Teams PracticeKorn Ferry Hay Group

Tom MolokoaneHead of Market Access Novo Nordisk



Dr Jacqui MiotHealth Economist Researcher and Senior LecturerUniversity of Witwatersrand

Prof Morgan ChettyMedical Doctor Deputy ChairmanSAMCCCEO KwaZulu Natal Managed Care Coalition

Lauren PretoriusCEOCampaigning for Cancer

Jessica KolbergBusiness Unit Manager Speciality Care Division Neonatology OncologyAbbvie

Dr Joatildeo CarapinhaSenior Market Access AnalystCarapinha amp Company

Karina RogersMarketing ManagerAurobindo Pharma

Vaychel RamanHead of Market AccessNovartis

Shelley McGeeHealthcare Policy amp Patient Access ManagerSanofi

Niel DassGeneral ManagerKenza Health

Marc BlockmanAssociate Professor Division of Clinical PharmacologyUniversity of Cape TownCommittee MemberMedicines Control CouncilCommittee MemberEssential Drugs List


Wesley HughesCustomer Excellence ManagerAbbvie

SECTION 1

lsquoSouth Africa needs usrsquo

KEYNOTE MARKET ACCESS DEBATESThis series of three expertly moderated panels examines some of the most contentious issues from all sides in order to encourage co-operation and understanding between different counterparties

Risk sharing in South African healthcare bull The case for and against risk sharing and appraisal of motives

bull Examples where risk sharing has and hasnrsquot worked

bull The suitability of international models for the South African market

bull What forms of risk sharing could be considered

bull How could these be implemented in a South African context What governance and frameworks are required

Standardize pharmacoeconomic analysis to drive towards a unified HTAbull What is the requirement for guidelines or a unified HTA process

How big an impact will guidelines around cost effectiveness models have on both the pharmaceutical industry and payer

bull Breaking the deadlock on voluntary submissions how can pharma be motivated to partake and how important is it

bull How can a standardized submission process best be introduced to enable optimum productivity

bull How could the roll-out of the standardized HTA work and in what time frame could this happen

How to avoid stock-outs and get drugs to your patients quickerbull How big an impact have stock-outs had on the South African

healthcare system

bull What have been the driving forces behind them

bull What solutions are there on both the industry and government side to address this

bull When will budget from the Ministry of Finance enable the implementation of new electronic systems

bull What experiences have there been in other countries

bull How can we best collaborate to ensure access to essential medicines

EXECUTIVE PANELISTS



Marc BlockmanAssociate Professor Division of Clinical PharmacologyUniversity of Cape TownCommittee Member Medicines Control CouncilCommittee Member Essential Drugs List


SECTION 2

Achieve real pharma-payer collaboration to optimize access for all parties

High Cost Specialty Medicines in SA ndash Industry Challenges and Opportunitiesbull The medicine cost experience and utilisation Discovery Health

Medical Scheme perspective

bull Find out how the Medicine Pricing Framework in South Africa impacts successful collaboration with all the stakeholders

bull What are the Risk Sharing Access Opportunities in South Africa and how you can take advantage of upcoming opportunities


Standardization of requirements and processes what the challenges are what can be done in the current atmosphere and beyondbull Comprehend the current managed care market landscape and the

differences in processes that leads to difficulties in standardizing requirements

bull Learn the scope of what can be standardized in the current scenario and how different service providers can join forces to achieve it

bull Recognize what steps need to be put in place in order to achieve a greater degree of harmonization amongst competing players in the space for the betterment of the South African patient


Develop long-term partnerships between Pharma and medical practitionersbull What do Medical Practitioners need to know about Pharmaceutical

products

bull 2Health Care Reform- The impact on Health Care systems and Pharma

bull Patient access to medicines and the challenges involved

Prof Morgan ChettyMedical Doctor Deputy Chairman SAMCCCEO KwaZulu Natal Managed Care Coalition

Achieve long term engagement with patients for holistic healthcare and optimal follow upbull Learn which initiatives involving long-term patient engagement

have worked well in both the public and private sector

bull Examine case studies of badly managed engagement for example TB

bull Identify which available tools we are underutilizing in order to improve patient engagement

bull Witness innovative frameworks and how to implement them to engage and include medical staff


Conference Agenda


INTERNATIONAL SPOTLIGHT Lessons from beyond Africa

Establish public-private partnerships in a developing and economically diverse market A case study on BrazilThis session will examine experiences from Brazilian markets on how they have addressed some of the challenges that the South African healthcare system is facing

bull Hear directly from ANVISA how they made key changes for a public-private partnership and how they decided timelines for roll-out

bull Understand the reactions of the government and private sector along the way to best anticipate potential challenges

bull Witness how the Brazilian frameworks for public-private partnerships could be transferred to the South African market and identify the differences that could prove stumbling blocks

bull Learn how the government and the private sector can support each other through the process


Apply international insights and gap analysis to South Africa to strengthen market accessbull Identify quality gaps in pharmacoeconomic research in South Africa

to improve patient access

bull Highlight policy gaps in South Africa to strengthen market access policy

bull Explore pricing gaps in South Africa to boost patient access through floors ceilings and corridors on pharmaceutical prices

bull Apply international research in South Africa to fill the gaps and drive innovation


SECTION 3

Optimize pricing and business strategy to best supply medicines to the market

PANEL Make the shift from maximum to optimum pricing to create a sustainable business modelbull Debate how to balance short-term targets with a long-term vision

on healthcare and sales to ensure future profitability

bull Examine the way South Africa is approached by headquarters in relation to other BRIC nations and whether this impacts on pricing options

bull Understand to what extent European market dynamics relate to South Africa and what aspects can be applied

bull Discuss the viability of a dual strategy for both the public and private sector and how it can be effectively implemented

bull Pinpoint what is needed from government and payers to support this




Navigate through current CAMS legislation to establish and maintain a sustainable brandbull Steer your business in alignment with CAMS to overcome existing

uncertainty and strategize your business going forward

bull Optimize consumer brand and market insights to design an effective and actionable plan for your business


Develop a winning methodology in preparing and submitting dossiers for HTAsbull Learn what costs you should and shouldnrsquot be including in your

pharmacoeconomic assessments

bull Overcome the challenge of a lack of local data and effectively model disease burden on society

bull Ensure you develop a clear message and value proposition by recognizing the common mistakes and avoiding them

bull Understand how to engage effectively with your payers




Conference Agenda

Foster collaboration to deliver value throughout your organisation to patientsbull Understand how different parts of the organisation need to work

together to deliver value for patients payers and physicians

bull Learn how to break down silos to reduce the barriers to necessary collaborations

bull Hear how the challenges encountered by organisations as they work to succeed in todayrsquos collaborative pharma environment are uncovered

bull Drawing on research from the sector look at how organisations can create the individual team and organizational capability to support real collaboration in increasingly complex healthcare systems


SECTION 4

Master cross-functional collaboration to ensure commercial excellence in a modern healthcare system

Integrate market access into your marketing strategy in order to maximize commercial returnsbull Attitude based change ndash learn how to help marketing teams

understand the role of market access to encourage collaboration from the ground up

bull Hear key strategies to avoid information being lost and miscommunicated between teams internally

bull Ensure a consistent message with your customers and key stakeholders by understanding how to integrate a market access approach into your marketing strategy

bull Understand how to integrate market access into your key account strategy into marketing strategy to improve brand value


Achieve sales force effectiveness in an increasingly saturated market placebull The decline of the traditional sales rep model - Learn how

to effectively work with reduced resources

bull Discuss strategies to improve the reputation of the sales rep to gain more open communication with clients

bull Learn from best practices on how to manage key accounts and optimize CRM systems to better work with clients

bull Out of industry Lessons learnt from other sectors on how they continue to increase commercial returns in the South African market


Incorporate the patient voice into your strategy to provide a better standard of care for your customersbull Identify how patient access programmes and risk sharing models will

improve patient access to essential medicines in South Africa

bull Learn what patient groups need and how they engage with government and medical schemes to increase reimbursement for your products

bull Discover new approaches to help pharma work with patients to improve education and access to drugs


PANEL Wersquore all in this together ndash ensure your marketing market access amp medical teams best work togetherbull Adopt strategies that improve cross-team communication to avoid

information being lost

bull Understand how a market access approach will enhance your marketing strategy and how to integrate your key account strategy into this

bull Hear expert insight on the optimum business unit structure across top pharma companies in South Africa




CASE STUDY Understand the effects of transformational leadership on your salespersonrsquos intention to quit and the impact of this on your organizationrsquos bottom linebull Examine South African sales rep feedback on their job satisfaction

bull Understand trends in sales rep commitment to their organisation

bull Evaluate sales rep perception of the ethical climate of their employer and the impact this has on their attitude towards their work


PANEL Deliver 21st century marketing in a medical contextbull Explore which of the marketing methodologies provide reliably strong ROI

bull Determine how social media can be integrated into your marketing strategy to best engage with the market

bull Understand the differences between generics ethical and CAMS approaches and what can be learnt from each

bull Examine successful marketing campaigns by pharma companies globally and what can be learnt from them to enhance your marketing strategy





Conference Agenda



T he pharmaceutical industry in South Africa suffers from poor image which

is making it difficult to readily enter into fruitful cooperation with the government

In South Africa pharma is an easy target for criticism Shying away from telling its own story directly to the public the industry has failed to establish itself as a trusted partner in healthcare Seen as profit-driven pharma doesnrsquot inspire the confidence necessary to build a sustainable relationship with the government or patients But that assessment isnrsquot fair ldquoWe do a lot to improve healthcare Thatrsquos why we exist We live to find new medicines we are driven by the passion of people who wake up in the morning to deliver new molecules that address a myriad of diseases including cancer HIVAIDS or other devastating communicable and non-communicable illnesses Making money is a by-productrdquo said Konji Sebati CEO The Innovative Pharmaceutical Association South Africa (IPASA) Changing this perception is high on Dr Sebatirsquos agenda ldquoWe havenrsquot told our story because wersquove always had our backs against the wall In that situation it is natural to throw your hands in the air and do nothingrdquo

Keeping patents is part of the problem

The industry has received particularly strong disapproval over their insistence on maintaining patents In South Africa there is a 20-year period of product protection during which generic companies cannot produce a given molecule After the patent lapses itrsquos everybodyrsquos game Many activists oppose this piece of legislation Some argue against patents altogether others say the period

of protection should be shortened yet others fight to make it impossible to extend intellectual property rights to products described asldquoincremental innovationrdquo

While itrsquos easy to oppose patents those arguing against them need to realize two things For example the clock starts ticking at the moment of discovery which happens before clinical trials can begin and with registration delays it is easily ten years before a drug reaches patients ldquoBy then you are usually left with 10-12 years of protectionrdquo Dr Sebati said

Another far more important realization is that incremental innovation needs to be protected because without it there is no chance for real breakthroughs The development of insulin is a good example Dr Sebati described ldquoIt started with large needles frequent injections constant blood sugar measurements etc Now you have once-daily administration jet injectors insulin pumps patches ndash none of that would be available without incremental innovationrdquo

Too much regulation doesnrsquot leave room to maneuver

But image problems arenrsquot the only issues keeping up pharma execs late at night ldquo[Pharma] in South Africa is highly regulated to a point where the amount of legislation you have to abide by makes it very challenging to innovate Regulation is good but it should be balanced in a way that leaves room for growth technology knowledge transfer and cooperationrdquo Dr Sebati explained

For example Dr Sebati proposed there should be an opportunity to introduce different pricing policies for the public and private sectors With 84 of South African population covered by the public insurance it should be made possible to introduce tiered pricing for the public sector ldquoWe could charge market prices for the private sector and lower the prices for the public sector with the government guarantee of volume purchasedrdquo Dr Sebati pointed out ldquoIdeally we would be able to negotiate with the government so that cutting-edge medicines

eyeforpharma caught up with Konji CEO of IPASA

By Zuzanna Fiminska

Continued

INSIGHT

Opportunities for solution providers

Business opportunities include

bull 1-to-1 meetings with key decision makers

bull Demonstrate thought leadership to a room of senior level executives

bull Show off your latest products and services in our exhibition hall

bull Build your brand with exclusive promotional opportunities

bull Host interactive workshops with core clients and prospects

and much more

eyeforpharma on demand grants you access to exclusive reports ndash plus audio video reports and whitepapers from ALL of our market access and commercial conferences and research projects

Access eyeforpharma on demand for a 4 week taster with a Gold Pass

See more

bull The foresight to anticipate whatrsquos next

bull The inspiration to explore whatrsquos possible

bull The edge to go above and beyond

Maximise your return on investment at this industry-leading event by increasing your profile with our exciting range of sponsorship opportunities contact

Joseph HargreavesBusiness Development Managereyeforpharma+44 207 375 7583jhargreaveseyeforpharmacom


reach publicly-funded patients too This way we could support government on access to all medicines irrespective of it being a generic or an originator medicine to the public sector as well but currently the law doesnrsquot allow thatrdquo

As a resolve to the status quo Dr Sebati suggests that there should be an open line of communication between pharma and the government which could include regular meetings of the partners to discuss issues and to strategize together on the best ways to deliver healthcare to all ldquoWe should have a forum where we meet every three months or so to discuss healthcare issuesrdquo Dr Sebati offered This way would enable the government and pharma to deal with each other in an open and evidence-based manner In addition it would facilitate problem solving as issues arise ldquoWe have recently been inundated with questions about stock-outs at healthcare facilities when members know that their medicines have definitely left the warehouses a clear indication of lacking inventory control skills efficient logistics and distribution plans Pharma is well-positioned to help We have the expertise We know logistics We can partner with the government and train people I would very much wish to see that cooperation with time I donrsquot want us to only talk to each other when there is a crisisrdquo

Nevertheless the government is not the only stakeholder that needs to be brought on board Conscious of that Dr Sebati is now looking for the best way to cooperate with eg patient groups Although still unclear about the best manner in which to proceed shersquos looking at ways that can lead to a sustainable model of cooperation ldquoThatrsquos one of the things we can do to build bridges with our most important stakeholder the patientrdquo Dr Sebati stated

Accusations over medicine costs

Pharma also have to face accusations from some funders asserting that the biggest cost drivers in healthcare are medicines Such attitude ignores the many factors around the discovery and the positive wave of new life-saving life-prolonging personalized medicines that will be approved in the coming years As a result of those approvals those drugs will shorten the disease suffering get patients well and back to work earlier with less side effects and a huge economic benefit to the government in the end ldquoWhat we should all

be doing as health partners and in this health value chain is spend less time pointing fingers and fighting battles through the media and more time sitting together and with government addressing the funding requirement for these medicines Pricing is already regulated This debate should no longer be happeningrdquo

In spite of all these problems incremental steps toward improving the situation are being made and with some good will from all participating stakeholders interests can be aligned and South Africarsquos healthcare system can go a long way

from previous

ldquo Spend less time pointing fingers and fighting battles through the media and more time sitting together and with government addressing the funding requirement for these medicinesrdquo

Registration choose your pass type

Delegate DetailsMrMrsMsDr First name Last name Company PositionTitle Telephone Fax Email Address Postcode Country

PaymentI enclose a chequedraft for (Payable to FC Business Intelligence Ltd)

Please invoice my company Purchase Order Number Please charge my credit card Amex Visa Mastercard

Credit card number Expiry date Security number Name on card Signature

wwweyeforpharmacomsouthafricaregisterphp

1 ONLINE

Send this form by fax to +44 20 7375 7172

4 FAX

The eyeforpharma Registration Team at registereyeforpharmacom

3 E-MAIL

eyeforpharma on +44 20 7375 7222

2 CALL

4 Easy Ways To Register

Today

Last Chance ndash Expires 19 February $1850 R 30400 $750 R 12300 $650 R 10700

Full Price $2000 R 32900 $800 R 13000 $700 R 11500

For Solution Providers amp Consultants

Last Chance ndash Expires 19 February $1550 R25500 $650 R 10700 $550 R 9055

Full Price $1700 R27900 $700 R 11500 $600 R 9870

For Pharma amp Biotech Collaboration Pass Gold Silver

GROUP RATE MOST POPULAR

TERMS amp CONDITIONS Places are transferable without any charge Cancellations before 8th February 2016 incur an administrative charge of 25 if you cancel your registration after 8th February 2016 we will be obliged to charge the full fee Please note ndash you must notify eyeforpharma in writing of a cancellation or we will be obliged to charge the full fee The organizers reserve the right to make changes to the programme without notice All prices displayed are exclusive of VAT unless otherwise stated but VAT will be charged where applicable at the prevailing rate on the invoice date and the relevant details will appear on the invoice NB FULL PAYMENT MUST BE RECEIVED BEFORE THE EVENT

3Ms Collaboration Pass

Bring your marketing market access and medical teams along Get 3 gold passes which include

bull Access to all conference sessions exhibition amp networking area

bull Access to speaker pdf slides and audio

bull 4 week subscription to eyeforpharma On Demand includes access to all event materials since 2013 and our premium reports More details here eyeforpharmacomon-demand

See prices below Email Giselle on GQuartineyeforpharmacom

Gold Pass




Silver Pass



Conversion rate as of the 13 January 2016











efpCEMA












LimitedPasses

Available

CEMA South Africa 2016 is the arena for senior level pharma executives across the 3Ms (Market Access Marketing and Medical) Theyrsquoll be joining government private medical aids payers and key decision makers who are keen to escape silos and learn how to best work together to build a more robust and widely accessible healthcare system for South Africa

The summit will help the commercial marketing and medical teams to work together to ensure the message shared to all stakeholders is consistent Furthermore yoursquoll have the opportunity to get clear guidelines from government and payers in terms of what they need from you in order to guarantee market entry and patient access to essential medicines

Over 2 days this event will inspire constructive debate and foster collaboration it has been specially designed for South African pharma and is the only one to finally give pharma a voice Not only will you learn from keynote panels exclusive case studies and real life business models from 25+ expert speakers yoursquoll also have the opportunity to speak directly with the key decision makers This is an event only for those who are serious about tackling the obstacles preventing South African health development

With all of this at your fingertips yoursquoll leave with genuine insights on how to achieve true commercial success and remove barriers to prescribing

Reserve your place amongst the most innovative minds in commercial marketing and market access ndash visit our website to register wwweyeforpharmacomsouthafrica or use the registration form enclosed

See you in Johannesburg

Welcome to the eyeforpharma Commercial Excellence and Market Access (CEMA) 2016 Summit Herersquos what attendees have

said about our previous commercial and market access events

Donrsquot just take our word for it

ldquo I found the congress exceptionally informative especially at this time when the pharma industry is going through a major change in defining new commercial modelrdquo

Quentin van der Merwe Sales Excellence Director GlaxoSmithKline

ldquo I came away from the conference feeling like I had some useful insights to share with my colleagues and ideas that could be implemented easily to further enhance our strategyrdquo

Carlyn Villani Brand Manager Roche

ldquo A fascinating meeting of diverse speakers who outlined numerous themes around the need to prove the validity and trustworthiness of RWE versus RCTs with an emphasis on ldquoreal timerdquo versus ldquoreal worldrdquo Thank you eyeforpharmardquo

Karel Mechelse Market Access Strategy Leader Bayer

ldquo Marketing with a purpose is all about creating unique and sustained value for patients and familiesenabling them with differentiated solutions to live the life they choose rather than one dictated by the diseaserdquo

Bharat Tewarie EVP amp Chief Marketing Officer UCB

Achieve real pharma- payer collaboration to streamline market access

bull Speak directly with Discovery Health and Metropolitan to better understand the decision making process and develop a better strategy for your future submissions

bull Learn what physicians find valuable and start supporting them to build long-term relationships and secure optimal market share

Optimize pricing and provision to guarantee entry to market

bull Make the shift from maximum to optimum pricing to create a sustainable business model

bull Evaluate strategies to address supply security and discuss how pharma can collaborate with government to ensure access to essential medicines

bull Work with the Pricing Committee to develop a winning methodology in preparing HTA dossiers

Master cross-functional collaboration to increase patient access to essential drugs and boost returns

bull Integrate a market access approach into your marketing strategy to ensure a consistent message with all customers and stakeholders

bull Improve the reputation of sales teams despite reduced resources

Agenda at a glance


Shakira BrowneHead of Commercial Excellence South Africa

Giselle QuartinHead of Marketing South Africa

Blair GottschoHead of Operations


























SECTION 1














healthcare system






EXECUTIVE PANELISTS





SECTION 2













products










Conference Agenda















SECTION 3























Conference Agenda







SECTION 4






































Conference Agenda















By Zuzanna Fiminska

Continued

INSIGHT








and much more



See more














from previous








1 ONLINE


4 FAX


3 E-MAIL


2 CALL


Today


Full Price $2000 R 32900 $800 R 13000 $700 R 11500



Full Price $1700 R27900 $700 R 11500 $600 R 9870










Gold Pass




Silver Pass














efpCEMA












LimitedPasses

Available


























SECTION 1














healthcare system






EXECUTIVE PANELISTS





SECTION 2













products










Conference Agenda















SECTION 3























Conference Agenda







SECTION 4






































Conference Agenda















By Zuzanna Fiminska

Continued

INSIGHT








and much more



See more














from previous








1 ONLINE


4 FAX


3 E-MAIL


2 CALL


Today


Full Price $2000 R 32900 $800 R 13000 $700 R 11500



Full Price $1700 R27900 $700 R 11500 $600 R 9870










Gold Pass




Silver Pass














efpCEMA












LimitedPasses

Available














SECTION 3























Conference Agenda







SECTION 4






































Conference Agenda















By Zuzanna Fiminska

Continued

INSIGHT








and much more



See more














from previous








1 ONLINE


4 FAX


3 E-MAIL


2 CALL


Today


Full Price $2000 R 32900 $800 R 13000 $700 R 11500



Full Price $1700 R27900 $700 R 11500 $600 R 9870










Gold Pass




Silver Pass














efpCEMA












LimitedPasses

Available

SECTION 4






































Conference Agenda















By Zuzanna Fiminska

Continued

INSIGHT








and much more



See more














from previous








1 ONLINE


4 FAX


3 E-MAIL


2 CALL


Today


Full Price $2000 R 32900 $800 R 13000 $700 R 11500



Full Price $1700 R27900 $700 R 11500 $600 R 9870










Gold Pass




Silver Pass














efpCEMA












LimitedPasses

Available














By Zuzanna Fiminska

Continued

INSIGHT








and much more



See more














from previous








1 ONLINE


4 FAX


3 E-MAIL


2 CALL


Today


Full Price $2000 R 32900 $800 R 13000 $700 R 11500



Full Price $1700 R27900 $700 R 11500 $600 R 9870










Gold Pass




Silver Pass














efpCEMA












LimitedPasses

Available








and much more



See more














from previous








1 ONLINE


4 FAX


3 E-MAIL


2 CALL


Today


Full Price $2000 R 32900 $800 R 13000 $700 R 11500



Full Price $1700 R27900 $700 R 11500 $600 R 9870










Gold Pass




Silver Pass














efpCEMA












LimitedPasses

Available







1 ONLINE


4 FAX


3 E-MAIL


2 CALL


Today


Full Price $2000 R 32900 $800 R 13000 $700 R 11500



Full Price $1700 R27900 $700 R 11500 $600 R 9870










Gold Pass




Silver Pass














efpCEMA












LimitedPasses

Available











efpCEMA












LimitedPasses

Available

e4p cema16 sa brochure v26

Documents